Yarrow Bioscience Inc

NASDAQ:YARWHealthcare · Biotechnology

Mkt Cap$185.16M

Float9.3M

Shares O/S9.3M

Inst Own2.9%

Div Yield101.00%

Dilution

-0.50%$19.90

AH$19.90+0.00%vs close

Mkt Cap$185.16M

Float9.3M

O/S9.3M

Vol

$ Vol

RVOL

Inst Own2.9%

Earnings

Div Yield101.00%

Dilution

NASDAQ:YARW$19.90-0.50%

MCap$185.16M

Float9.3M

O/S9.3M

Inst Own2.9%

Dilution

Phase Distribution

33 lead-sponsored trials·1 active·27 completed

Phase 16

Phase 1/21

Phase 217

Phase 39

(5 more as collaborator)

Status Overview

Recruiting1

Completed27

Stopped5

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials

Sponsor role

Status

Phase

Phase 3
Completed
A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne
FMX-101, 4% minocycline foam, Vehicle Foam
Acne Vulgaris
Enrollment
466
Start
May 2016
Primary Completion
Oct 2017
Completion
Oct 2017
NCT02815267
Phase 3
Completed
A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne
FMX-101, 4% minocycline foam, Vehicle Foam
Acne Vulgaris
Enrollment
495
Start
May 2016
Primary Completion
Oct 2017
Completion
Oct 2017
NCT02815280
Phase 3
Completed
A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
FMX103 minocycline foam 1.5%, Vehicle foam
Facial Papulopustular Rosacea
Enrollment
751
Start
Jun 2017
Primary Completion
Aug 2018
Completion
Sep 2018
NCT03142451
Phase 3
Completed
A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris
FMX101, Vehicle Foam
Acne Vulgaris
Enrollment
1,488
Start
Jul 2017
Primary Completion
Sep 2018
Completion
Sep 2018
NCT03271021
Phase 3
Completed
A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea
FMX103 1.5%
Papulopustular Rosacea
Enrollment
504
Start
Sep 2017
Primary Completion
Jan 2019
Completion
Jan 2019
NCT03276936
Phase 3
Terminated
Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)
5 mg Serlopitant Tablets
Pruritus, Prurigo Nodularis +2
Enrollment
558
Start
Mar 2018
Primary Completion
Apr 2020
Completion
Jun 2020
NCT03540160
Phase 3
Completed
Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
5mg Serlopitant Tablets, Placebo Tablets
Pruritus, Prurigo Nodularis
Enrollment
285
Start
May 2018
Primary Completion
Jan 2020
Completion
Feb 2020
NCT03546816
Phase 3
Completed
Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
5mg Serlopitant Tablets, Placebo Tablets
Pruritus, Prurigo Nodularis
Enrollment
295
Start
Aug 2018
Primary Completion
Jan 2020
Completion
Feb 2020
NCT03677401
Phase 3
Completed
A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
FMX103 minocycline foam 1.5%, Vehicle foam
Facial Papulopustular Rosacea
Enrollment
771
Start
Jun 2017
Primary Completion
Jul 2018
Completion
Jul 2018
NCT04608500
Phase 2
Completed
Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)
MK0594
Urinary Incontinence, Overactive Bladder
Enrollment
557
Start
Feb 2006
Primary Completion
Aug 2007
Completion
Sep 2007
NCT00290563
Phase 2
Terminated
A Study of MK0594 in Patients With Alcohol Dependence (0594-020)
Comparator: MK0594 5 mg/day, Comparator: MK0594 1 mg/day
Alcohol Dependence
Enrollment
162
Start
Feb 2009
Primary Completion
Mar 2010
Completion
Mar 2010
NCT00835718
Phase 2
Terminated
Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Rosacea Patients
Topical Minocycline Foam FXFM244
Rosacea
Enrollment
21
Start
Jun 2010
Primary Completion
Mar 2014
Completion
-
NCT01134991
Phase 2
Completed
Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients
Topical Minocycline Foam FXFM244
Impetigo
Enrollment
32
Start
Aug 2010
Primary Completion
Mar 2012
Completion
Apr 2012
NCT01171326
Phase 2
Completed
Clinical Study to Evaluate Tolerability and Safety of FXFM244 and to Monitor Clinical Effect in Acne Vulgaris Patients
Topical Minocycline Foam FXFM244
Acne Vulgaris
Enrollment
150
Start
Jan 2012
Primary Completion
Jun 2013
Completion
Jul 2013
NCT01362010
Phase 2
Completed
VPD-737 for Treatment of Chronic Pruritus
VPD-737, Placebo
Chronic Pruritus
Enrollment
257
Start
Oct 2013
Primary Completion
Dec 2014
Completion
Dec 2014
NCT01951274
Phase 2
Completed
A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)
serlopitant, Placebo
Prurigo Nodularis
Enrollment
128
Start
Jul 2014
Primary Completion
May 2016
Completion
Jun 2016
NCT02196324
Phase 2
Completed
Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients
FDX104 (4% Doxycycline)
Rash Due to Epidermal Growth Factor Receptor Inhibitors
Enrollment
24
Start
Oct 2014
Primary Completion
Oct 2015
Completion
Oct 2015
NCT02239731
Phase 2
Completed
Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea
FMX-103 1.5%, FMX-103 3%
Rosacea, Papulopustular Rosacea
Enrollment
233
Start
Sep 2015
Primary Completion
Aug 2016
Completion
Aug 2016
NCT02601963
Phase 2
Completed
Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis
Serlopitant High Dose, Placebo Oral Tablet
Pruritus, Atopic Dermatitis
Enrollment
484
Start
Nov 2016
Primary Completion
Jan 2018
Completion
Feb 2018
NCT02975206
Phase 2
Terminated
Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury
Serlopitant, Placebo
Pruritus, Burns
Enrollment
1
Start
Nov 2016
Primary Completion
Jan 2017
Completion
Jan 2017
NCT02975271
Phase 2
Completed
Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough
5 mg Serlopitant Tablets, Matching Placebo Tablets
Refractory Chronic Cough
Enrollment
185
Start
Oct 2017
Primary Completion
Aug 2018
Completion
Sep 2018
NCT03282591
Phase 2
Completed
Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis
5 mg Serlopitant Tablets, Matching Placebo Tablets
Pruritus, Psoriasis
Enrollment
204
Start
Nov 2017
Primary Completion
Oct 2018
Completion
Nov 2018
NCT03343639
Phase 2
Completed
Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin
5 mg Serlopitant Tablets, Matching Placebo Tablets
Pruritus
Enrollment
233
Start
Jan 2019
Primary Completion
Dec 2019
Completion
Jan 2020
NCT03841331
Phase 2
Completed
A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.
3% Minocycline Foam, 0.3% Adapalene Foam
Acne Vulgaris
Enrollment
446
Start
Sep 2019
Primary Completion
Feb 2020
Completion
Mar 2020
NCT04104685
Phase 2
Terminated
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.
VYN201 Gel, Vehicle Gel
Non-segmental Vitiligo
Enrollment
205
Start
Jun 2024
Primary Completion
Jul 2025
Completion
Sep 2025
NCT06493578

		Drug / Therapy	Title	Conditions	Enrollment				Link
Phase 3	Completed	FMX-101, 4% minocycline foam, Vehicle Foam	A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne	Acne Vulgaris	466	May 2016	Oct 2017	Oct 2017	NCT02815267
Phase 3	Completed	FMX-101, 4% minocycline foam, Vehicle Foam	A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne	Acne Vulgaris	495	May 2016	Oct 2017	Oct 2017	NCT02815280
Phase 3	Completed	FMX103 minocycline foam 1.5%, Vehicle foam	A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea	Facial Papulopustular Rosacea	751	Jun 2017	Aug 2018	Sep 2018	NCT03142451
Phase 3	Completed	FMX101, Vehicle Foam	A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris	Acne Vulgaris	1,488	Jul 2017	Sep 2018	Sep 2018	NCT03271021
Phase 3	Completed	FMX103 1.5%	A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea	Papulopustular Rosacea	504	Sep 2017	Jan 2019	Jan 2019	NCT03276936
Phase 3	Terminated	5 mg Serlopitant Tablets	Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)	Pruritus, Prurigo Nodularis	558	Mar 2018	Apr 2020	Jun 2020	NCT03540160
Phase 3	Completed	5mg Serlopitant Tablets, Placebo Tablets	Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis	Pruritus, Prurigo Nodularis	285	May 2018	Jan 2020	Feb 2020	NCT03546816
Phase 3	Completed	5mg Serlopitant Tablets, Placebo Tablets	Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis	Pruritus, Prurigo Nodularis	295	Aug 2018	Jan 2020	Feb 2020	NCT03677401
Phase 3	Completed	FMX103 minocycline foam 1.5%, Vehicle foam	A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea	Facial Papulopustular Rosacea	771	Jun 2017	Jul 2018	Jul 2018	NCT04608500
Phase 2	Completed	MK0594	Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)	Urinary Incontinence, Overactive Bladder	557	Feb 2006	Aug 2007	Sep 2007	NCT00290563
Phase 2	Terminated	Comparator: MK0594 5 mg/day, Comparator: MK0594 1 mg/day	A Study of MK0594 in Patients With Alcohol Dependence (0594-020)	Alcohol Dependence	162	Feb 2009	Mar 2010	Mar 2010	NCT00835718
Phase 2	Terminated	Topical Minocycline Foam FXFM244	Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Rosacea Patients	Rosacea	21	Jun 2010	Mar 2014	-	NCT01134991
Phase 2	Completed	Topical Minocycline Foam FXFM244	Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients	Impetigo	32	Aug 2010	Mar 2012	Apr 2012	NCT01171326
Phase 2	Completed	Topical Minocycline Foam FXFM244	Clinical Study to Evaluate Tolerability and Safety of FXFM244 and to Monitor Clinical Effect in Acne Vulgaris Patients	Acne Vulgaris	150	Jan 2012	Jun 2013	Jul 2013	NCT01362010
Phase 2	Completed	VPD-737, Placebo	VPD-737 for Treatment of Chronic Pruritus	Chronic Pruritus	257	Oct 2013	Dec 2014	Dec 2014	NCT01951274
Phase 2	Completed	serlopitant, Placebo	A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)	Prurigo Nodularis	128	Jul 2014	May 2016	Jun 2016	NCT02196324
Phase 2	Completed	FDX104 (4% Doxycycline)	Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients	Rash Due to Epidermal Growth Factor Receptor Inhibitors	24	Oct 2014	Oct 2015	Oct 2015	NCT02239731
Phase 2	Completed	FMX-103 1.5%, FMX-103 3%	Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea	Rosacea, Papulopustular Rosacea	233	Sep 2015	Aug 2016	Aug 2016	NCT02601963
Phase 2	Completed	Serlopitant High Dose, Placebo Oral Tablet	Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis	Pruritus, Atopic Dermatitis	484	Nov 2016	Jan 2018	Feb 2018	NCT02975206
Phase 2	Terminated	Serlopitant, Placebo	Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury	Pruritus, Burns	1	Nov 2016	Jan 2017	Jan 2017	NCT02975271
Phase 2	Completed	5 mg Serlopitant Tablets, Matching Placebo Tablets	Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough	Refractory Chronic Cough	185	Oct 2017	Aug 2018	Sep 2018	NCT03282591
Phase 2	Completed	5 mg Serlopitant Tablets, Matching Placebo Tablets	Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis	Pruritus, Psoriasis	204	Nov 2017	Oct 2018	Nov 2018	NCT03343639
Phase 2	Completed	5 mg Serlopitant Tablets, Matching Placebo Tablets	Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin	Pruritus	233	Jan 2019	Dec 2019	Jan 2020	NCT03841331
Phase 2	Completed	3% Minocycline Foam, 0.3% Adapalene Foam	A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.	Acne Vulgaris	446	Sep 2019	Feb 2020	Mar 2020	NCT04104685
Phase 2	Terminated	VYN201 Gel, Vehicle Gel	A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.	Non-segmental Vitiligo	205	Jun 2024	Jul 2025	Sep 2025	NCT06493578

1-25 of 33 trials

Search ClinicalTrials.gov for “Yarrow Bioscience”